2nd September 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Why do unethical pharmaceutical practices succeed?

A mandatory, enforceable code for ethical pharmaceutical marketing is required. The recent controversy over a specific brand of the painkiller paracetamol 650 mg tablet is more about the unethical marketing tactics of India’s pharmaceutical industry.

Active pharmaceutical ingredients (APIs) - marked with QR code

The inclusion of QR codes on APIs that are produced in India or imported and distributed is required by the Indian government in order to make it easier to track and trace the products throughout the supply chain.

Alembic receives Form 483 from the USFDA with two observations

Alembic Pharmaceuticals reported that from August 18 through August 30, 2022, the US Food and Drug Administration (USFDA) inspected the drug manufacturer’s injectable facility (F-3) in Karkhadi.

Aurobindo Pharma's biologics manufacturing arm invest around Rs 300 crore

Aurobindo Pharma announced plans to invest close to Rs 300 crore in the capacity expansion of biologics manufacturing facilities through its wholly owned subsidiary, CuraTeQ Biologics.

Govt granted approval to three states to establish bulk drug parks

The proposals from the three states- Himachal Pradesh, Gujarat, and Andhra Pradesh- under the Scheme for the “Promotion of Bulk Drug Parks, ” a program to aid in the nation’s drug manufacturing, have received “in-principle” approval from the Dept. of Pharmaceuticals.

Sanofi's Xenpozyme received US FDA approval as the first disease-specific therapy

US Food and Drug Administration (FDA) has approved Xenpozyme (olipudase alfa-rpcp) for the treatment of non-CNS manifestations of acid sphingomyelinase deficiency (ASMD) in adults and children.

Johnson & Johnson agreed to pay $40.5 million to settle a lawsuit related to opioid epidemic

A trial that was set to start next week has been postponed thanks to Johnson & Johnson’s decision to pay $40.5 million to resolve New Hampshire’s claims regarding the pharma company’s contribution to the nation’s opioid epidemic.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?